Medicus Pharma Closes Exchange Agreement, Registered Direct Offering, and Private Placements for Nasdaq Compliance
Medicus Pharma Ltd. entered into and closed an exchange agreement with Streeterville Capital, LLC on November 13, 2026, exchanging $10.5 million in principal amount of Secured Promissory Note A-1 for 105,000 non-convertible, non-voting preferred shares at $100 per share, carrying cumulative dividends at 8% per annum payable in kind. Concurrently, the company completed a registered direct offering of 97,973 common shares at $1.72 per share and pre-funded warrants to purchase up to 1,646,213 common shares at $1.71...
Key takeaways
Exchange agreement: $10.5 million of Secured Promissory Note A-1 exchanged for 105,000 non-convertible, non-voting preferred shares with 8% cumulative dividends payable in kind
Registered direct offering: 97,973 common shares at $1.72 per share and pre-funded warrants for 1,646,213 shares at $1.7199 per warrant, generating approximately $3.0 million in gross proceeds
Private placements: 726,730 common shares sold for approximately $1.25 million, with $750,000 investment by CEO Dr. Raza Bokhari
ATM sales: approximately 113,000 common shares sold for $0.35 million under at-the-market offering program
Nasdaq compliance: company believes it has regained compliance with Listing Rule 5550(b) with approximately $3.0 million in pro forma shareholders' equity
No placement agent or underwriter engaged; no underwriting discounts, commissions, or placement agent fees paid
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MDCX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.